MIDAS Pharma and Capsulution sign Cooperation Contract

The Ingelheim-based pharmaceutical company has entered into cooperation with the Berlin-based drug-delivery company

Our connections lead to innovation
(PresseBox) ( Berlin, Ingelheim, )
After having successfully carried out the first joint feasibility studies on the application of the LBL Technology® for the improved delivery of pharmaceutical substances, Midas Pharma and Capsulution have set up the framework for long-term cooperation.

The object of the cooperation contract, signed in June, is the joint implementation of projects for the development of improved pharmaceutical products for the pharmaceutical industry. The framework of the contract ensures the Midas Pharma GmbH access to the innovative technology of the Berlin-based start up company and provides in exchange their expertise in the downstream areas of the pharmaceutical value chain. In this way, Capsulution will be able to offer their pharmaceutical companies additional services in all issues concerning the procurement of pharmaceutical substances, pharmaceutical contract manufacturing, international license projects or the creation of registration dossiers.

“Midas Pharma with its worldwide subsidiary representations is present on the most important pharmaceutical markets and opens up for us a new range of market opportunities,” explains Alexander Herrmann, CFO of Capsulution. “We are very pleased that, with Midas, we have been able to acquire a very competent and reliable partner from the pharmaceutical industry,” adds Hermann. For Capsulution, the partnership offers the opportunity to strengthen the focus by widening the spectrum of services. “Our key competence is as always the development of innovative drug delivery systems for a targeted and secure application of the active pharmaceutical substance based upon our worldwide patented LBL Technology®,” states Herrmann. “On the other hand, so-called standard pharmaceutical services should be provided by a growing network of partners,” Hermann concludes.

For Midas also, the cooperation with Capsulation represents an important step forward: “The cooperation with Capsulution is a major contribution towards expanding our current range of products and services,” explains Marcus Stumpf, managing director of Midas. The wide-ranging application of Capsulution’s toolbox-like formulation platform delivers promising solution approaches in the development of various pharmaceutical products. In this sense, the cooperation of both companies is a win-win situation for Midas and Capsulution.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.